Juan Manuel Sanchez Hidalgo

Juan Manuel Sanchez Hidalgo

Auto-generated profile, based on publicly available information

Juan Manuel Sanchez Hidalgo

Department of Surgery, University Hospital Reina Sofia, Córdoba, Spain

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2019 in World Journal of Gastroenterology
Verified
Journal Article
Open access
JSJuan Manuel Sánchez-Hidalgo
Juan Manuel Sánchez-Hidalgo
LRLidia Rodríguez-Ortiz
Lidia Rodríguez-Ortiz
AAAlvaro Arjona-Sanchez
Alvaro Arjona-Sanchez
SRSebastián Rufián-Peña
Sebastián Rufián-Peña
ÁCÁngela Casado-Adam
Ángela Casado-Adam
JBJavier Briceño-Delgado
Javier Briceño-Delgado
The peritoneum is a common site of dissemination for colorrectal cancer, with a poorer prognosis than other sites of metastases. In the last two decades, it has been considered as a locoregional disease progression and treated as such with curative intention treatments. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the actual reference treatment for these patients as better survival results have been reached as compared to systemic chemotherapy alone, but its therapeutic efficacy is still under debate. Actual guidelines recommend that the management of colorectal cancer with peritoneal metastases should be led by a multidisciplinary team carried out in experienced centers and consider CRS + HIPEC for selected patients. Accumulative evidence in the last three years suggests that this is a curative treatment that may improve patients disease-free survival, decrease the risk of recurrence, and does not increase the risk of treatment-related mortality. In this review we aim to gather the latest results from referral centers and opinions from experts about the effectiveness and feasibility of CRS + HIPEC for treating peritoneal disease from colorectal malignancies.

13 February 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AAAlvaro Arjona-Sanchez
Alvaro Arjona-Sanchez
PBP. Barrios
P. Barrios
EBE. Boldo-Roda
E. Boldo-Roda
BCB. Camps
B. Camps
JCJ. Carrasco-Campos
J. Carrasco-Campos
SRS. Rufián-Peña
S. Rufián-Peña
Local relapse and peritoneal carcinomatosis (PC) for pT4 colon cancer is estimated in 15,6% and 36,7% for 12 months and 36 months from surgical resection respectively, achieving a 5 years overall survival of 6%. There are promising results using prophylactic HIPEC in this group of patients, and it is estimated that up to 26% of all T4 colon cancer could benefit from this treatment with a minimal morbidity. Adjuvant HIPEC is effective to avoid the possibility of peritoneal seeding after surgical resection. Taking into account these results and the cumulative experience in HIPEC use, we will lead a randomized controlled trial to determine the effectiveness and safety of adjuvant treatment with HIPEC vs. standard treatment in patients with colon cancer at high risk of peritoneal recurrence (pT4). The aim of this study is to determine the effectiveness and safety of adjuvant HIPEC in preventing the development of PC in patients with colon cancer with a high risk of peritoneal recurrence (cT4). This study will be carried out in 15 Spanish HIPEC centres. Eligible for inclusion are patients who underwent curative resection for cT4NxM0 stage colon cancer. After resection of the primary tumour, 200 patients will be randomized to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy in the experimental arm, or to systemic chemotherapy only in the control arm. Adjuvant HIPEC will be performed simultaneously after the primary resection. Mitomycin C will be used as chemotherapeutic agent, for 60 min at 42–43 °C. Primary endpoint is loco-regional control (LC) in months and the rate of loco-regional control (%LC) at 12 months and 36 months after resection. We assumed that adjuvant HIPEC will reduce the expected absolute risk of peritoneal recurrence from 36% to 18% at 36 months for T4 colon-rectal carcinoma. NCT02614534 ( clinicaltrial.gov ) Nov-2015.

24 December 2008 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
JBJavier Briceño
Javier Briceño
RCRubén Ciria
Rubén Ciria
MPMaría Pleguezuelo
María Pleguezuelo
MMManuel de la Mata
Manuel de la Mata
JMJordi Muntané
Jordi Muntané
PLPedro López-Cillero
Pedro López-Cillero
: The aim of this study was to determine the influence of donor graft steatosis on overall outcome, viral recurrence, and fibrosis progression in orthotopic liver transplantation (OLT) for hepatitis C virus (HCV) cirrhosis. One hundred twenty patients who underwent OLT for HCV cirrhosis between 1995 and 2005 were included in the study. Donor steatosis was categorized as absent (0%-10%; n = 40), mild (10%-30%; n = 32), moderate (30%-60%; n = 29), or severe (>60%; n = 19). A Cox multivariate analysis for marginal donor variables and a Model for End-Stage Liver Disease index were performed. Fibrosis evolution was analyzed in liver biopsies (fibrosis < 2 or ≥2) 3, 6, and 12 months post-OLT and in the late post-OLT period. Fifty-six grafts were lost (46%). The survival of the grafts was inversely proportional to donor liver steatosis: 82%, 72%, and 72% at 1, 2, and 3 years post-OLT in the absence of steatosis; 73%, 63%, and 58% with mild steatosis; 74%, 62%, and 43% with moderate steatosis; and 62%, 49%, and 42% with severe steatosis (P = 0.012). HCV recurrence was earlier and more frequent in recipients with steatosis > 30% (46% versus 32% at 3 months, P = 0.017; 58% versus 43% at 6 months, P = 0.020; 70% versus 56% at 12 months, P = 0.058; and 95% versus 69% at 3 years post-OLT, P = 0.0001). Graft survival was lower in alcoholic liver disease recipients versus HCV recipients when steatosis was >30% at 3, 6, and 12 months post-OLT (P = 0.042) but not when steatosis was 30%. OLT with >30% steatotic donor livers should be precluded in HCV recipients. Liver Transpl 15:37–48, 2009. © 2008 AASLD.

14 May 2018 in World Journal of Gastroenterology
Verified
Journal Article
Open access
JSJuan Manuel Sanchez-Hidalgo
Juan Manuel Sanchez-Hidalgo
MDManuel Duran-Martinez
Manuel Duran-Martinez
RMRafael Molero-Payan
Rafael Molero-Payan
SRSebastian Rufian-Peña
Sebastian Rufian-Peña
AAAlvaro Arjona-Sanchez
Alvaro Arjona-Sanchez
JBJavier Briceño-Delgado
Javier Briceño-Delgado
Gastrointestinal stromal tumors: A multidisciplinary challenge

1 May 2010
Verified
Journal Article
Closed access
PDF file
JBJavier Briceño
Javier Briceño
ÁNÁlvaro Naranjo
Álvaro Naranjo
RCRubén Ciria
Rubén Ciria
RDRafael Diaz-Nieto
Rafael Diaz-Nieto
JHJuan Manuel Sanchez Hidalgo
Juan Manuel Sanchez Hidalgo
PLPedro López-Cillero
Pedro López-Cillero
Objective To examine the effectiveness of fibrin sealants as supportive treatment to improve hemostasis and decrease the incidence of bile leakage and intra-abdominal collections. Design Prospective, controlled, quasiexperimental study. Setting Tertiary referral center, University Hospital Reina Sofía. Patients A total of 115 patients (58 in the control group and 57 in the collagen sponge group) scheduled for conventional hepatectomies. Interventions Patients were distributed into groups for major and minor hepatectomies with or without application of a carrier-bound collagen sponge on the raw surface of the liver. Main Outcome Measures The main outcome measures were postoperative mortality, incidence and severity of postoperative surgical complications, and length of hospital stay. The secondary outcome measures were postoperative drainage output volume, transfusion requirements, and changes in biochemical parameters (hemoglobin, bilirubin, alanine aminotransferase, and platelet levels). Results The fibrin sealant after major liver resection was effective for decreasing drainage volume (mean [SD] volume, 1124.7 [842.8] mL in the control group and 691.2 [499.5] mL in the collagen sponge group; P = .007) with a higher volume of output by drain each postoperative day in the control patients (P = .003); postoperative blood transfusion requirements (18.9% vs 7.0%, respectively; P = .04); moderate to severe postoperative complications (21% vs 8%, respectively; P = .03); and mean (SD) hospital stay (12.6 [6.7] vs 9.6 [5.1] days, respectively; P = .03). Conclusion The use of a new carrier-bound collagen sponge after major liver resection may be recommended because of its clinical and cost-savings effectiveness.

1 February 2016 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
FCFrancisco Cristóbal Muñoz Casares
Francisco Cristóbal Muñoz Casares
FMFrancisco Javier Medina-Fernández
Francisco Javier Medina-Fernández
AAAlvaro Arjona-Sanchez
Alvaro Arjona-Sanchez
ÁCÁ. Casado-Adam
Á. Casado-Adam
JSJ.M. Sánchez-Hidalgo
J.M. Sánchez-Hidalgo
FBF.J. Briceño
F.J. Briceño